At Foghorn, we pledge to partner with patients as we work to discover and develop new, effective therapies for a wide spectrum of diseases, including many types of cancer. Every member of our team is committed to making a difference in the lives of our fellow human beings.
Clinical trials are studies that are conducted to evaluate the safety and effectiveness of a new therapy. These studies are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
POLICY ON EXPANDED ACCESS (EA) TO INVESTIGATIONAL DRUGS
Currently, participation in clinical trials is the only way for patients to gain access to Foghorn’s investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.